The inclusion in the DOW is significant and we'll give it an upward bias. One of the best pharmaceutical companies in the world. There is competition and drug pipelines are a little tougher. A little expensive.
Has been disappointed with execution over the last few years. Feels they are aggressively redressing some of those concerns. Feels the stock is undervalued.
(A past top pick Feb 20/04. Up 4%.) Life-insurance side is growing nicely. Great exposure to wealth management. Like its geographic position encompassing the Far East.
(A past top pick Feb 20/04. Down 5%.) To own the stock, you have to be prepared for headline risks. Authorities in the US are looking up the regulations. Trading at 9 X earnings.